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[18F]FDG-PET Evaluation of Spinal Pathology in Patients in
Oncology: Pearls and Pitfalls for the Neuroradiologist
P.Y. Patel,

I. Dalal, and

B. Griffith

ABSTRACT
SUMMARY: [18F]FDG-PET is a widely used technique for speciﬁc evaluation of disease and treatment response in oncology. However,
the principles behind [18F]FDG-PET imaging allow a wide-ranging array of benign and malignant pathologies to be identiﬁed on both
initial and routine surveillance imaging. This is important for clinicians and radiologists, alike, in that effective and accurate evaluation
of malignancy and metastatic disease, speciﬁcally involving the spine and central nervous system, is crucial. In this article, we review
the normal and posttherapy appearance of the spine on [18F]FDG-PET, the various types and patterns of metastatic disease that
involve the spine and spinal cord, and, ﬁnally, important spinal pathologies that may mimic malignancy on [18F]FDG-PET.
ABBREVIATIONS: G-CSF ¼ granulocyte colony-stimulating factors; ISCM ¼ intramedullary spinal cord metastasis; SUV ¼ standard uptake value; SUVmax ¼
maximum standard uptake value

S

ince its inception in the mid-1970s, [18F]FDG-PET has grown
into a multifaceted tool with applications not only in cancer
imaging but in neurologic disorders, infection, inflammation,
and cardiac imaging.1 As one of the most quantitative imaging
techniques available for assessing metastatic disease, [18F]FDGPET/CT has become an essential imaging tool in the diagnosis,
staging, and management of cancer and cancer-related disease
during the past two decades.1 Although metastatic disease can
occur anywhere, the spine is of particular importance, not only
because it is the third most frequent site of distant metastatic disease but also because many nonmalignant processes, some of
which can appear nearly identical to metastatic foci on [18F]
FDG-PET, are frequently identified involving the spine during
the course of a patient’s routine oncologic work-up.2
While MR imaging is the most crucial imaging technique
used to assess spinal metastatic disease, various metastatic disease
patterns have been demonstrated on [18F]FDG-PET, which can
help in disease localization and assessment.2,3 Understanding
both the benefits and pitfalls of [18F]FDG-PET in evaluating the
spine is important, given the frequent use of PET and PET/CT in
both oncologic work-up and surveillance. This review will discuss
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general [18F]FDG-PET and, most important, nonmetastatic pitfalls that may appear similar on standard [18F]FDG-PET.

Normal Distribution of [18F]FDG in the Spine
In the assessment for metastatic disease in the spine, recognition of
the normal or physiologic appearance of [18F]FDG-PET is essential. Because [18F]FDG uptake in PET reflects tissue levels of cellular glucose metabolism, normal anatomic structures in the spine
can demonstrate variable degrees of hypermetabolic uptake.
Specifically, relative increases in physiologic [18F]FDG uptake have
been demonstrated in the spinal cord at the T11 and T12 levels
and, to a lesser degree, at the C4 level (Fig 1).4-6 Additionally, slight
relative physiologic uptake within the cord has also been noted at
the level of the atlas.7 While not definitively explained, it is theorized that the increased uptake in the lower thoracic cord is due to
inadequate clearance of the radiotracer from the artery of
Adamkiewicz, which originates from the aorta between T9 and
T11, and/or due to the relative increased cross-sectional area of the
spinal cord at the midcervical and lower thoracic levels with an
associated increased ratio of gray matter.4,5,7
Relative changes in physiologic uptake can also be noted
within the vertebral bodies, with background marrow uptake typically having a maximum standard uptake value (SUVmax) of
,3.8 Peak physiologic radiotracer uptake has been noted within
the lower thoracic vertebral bodies, typically between T8 and
T11, though standard uptake values (SUVs) are usually below
those of the liver.8,9 Additionally, although subtle, SUVs typically
demonstrate a gradual decrease both cranially and caudally.6,9
AJNR Am J Neuroradiol :
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Because this increased uptake often appears as focal areas within
the marrow and can be misleading on axial images, it is important to correlate with the sagittal and coronal planes. Because
[18F]FDG uptake is dependent on active hematopoietic marrow–
red marrow, studies have shown a gradual decrease in osseous
[18F]FDG uptake with increasing age as red marrow is replaced
by yellow marrow.8

Posttherapy Changes of the Spine

FIG 1. A 59-year-old man with lung cancer without metastatic disease.
Sagittal fused (A) and AC PET (B) images demonstrate physiologic [18F]
FDG uptake throughout the spine as well as focal physiologic [18F]FDG
spinal cord uptake at T11–T12 (arrows). Absent uptake in the midthoracic spine is related to previous radiation therapy. Fused indicates
fused PET and CT image; AC, attenuation-corrected.

Many cancer therapies play an important role in the oncologic
application of [18F]FDG-PET, with two of the most common being
granulocyte colony-stimulating factors (G-CSF) and radiation
therapy. G-CSF is a glycoprotein hormone used to treat chemotherapy-induced neutropenia and reduce infection severity by
stimulating hematopoietic progenitors.10 Diffusely increased, homogeneous radiotracer uptake is identified throughout the bone
marrow both during and after G-CSF administration in up to 87%
of patients.10,11 Given this diffuse marrow uptake, both bone metastases and benign bone lesions may be obscured or appear as
photopenic defects due to the relative hyperplastic bone marrow
(Fig 2).11 Although the optimal timeframe for follow-up PET/CT
in the setting of G-CSF therapy has not been determined, studies
have shown that bone marrow [18F]FDG uptake can remain elevated for up to 1 month after administration of G-CSF, with return
to plateau times ranging from 10 days to 1 month.11,12
Radiation therapy can also have considerable effects on normal
tissue, especially hematopoietic bone marrow. Specifically, radiation
therapy can cause immediate avid [18F]FDG uptake due to local
postradiation inflammation.10 Therefore, [18F]FDG-PET is typically
performed 8–12 weeks after completion of radiation therapy for
better assessment of the treatment response.13 In the subacute and
chronic stages after radiation therapy, treated areas of bone marrow
typically appear as photopenic regions,
matching the geographic radiation field
(Fig 3).10,11 Some patients have experienced [18F]FDG uptake in irradiated
bone marrow gradually decreasing
below baseline levels as early as 2–
8 days after therapy.14

Metastatic Disease of the Spine

FIG 2. A 62-year-old woman with breast cancer. Sagittal CT (A), AC PET (B), and fused (C) images
demonstrate a sclerotic (asterisk) and photopenic region (solid arrows) in the L1 vertebral body
consistent with a site of treated metastasis. Note the diffusely increased radiotracer uptake
through the remaining axial skeleton, which obscures multilevel osseous metastases seen on CT.
Fused indicates fused PET and CT image; AC, attenuation-corrected.
2
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The spine is the third most common
site for distant metastatic disease after
the lung and liver and is the most common site for osseous metastases, with
approximately 50%–70% of patients
with systemic cancer having spinal
involvement.2 Involvement of the spine
in the setting of cancer can be divided
into distant metastases, either through
hematogenous or lymphatic spread or
by extension from surrounding tissues,
including by local invasion or perineural spread.2 While the conventional
oncologic work-up for spinal metastatic disease involves detailed MR
imaging evaluation, [18F]FDG-PET is

often performed first during the initial
staging and can offer valuable information, given its reliance on metabolic
activity.3

Metastatic Disease

FIG 3. A 48-year-old man with B-cell lymphoma of the gastric fundus after radiation therapy.
Sagittal CT (A), AC PET (B), and fused (C) images demonstrate a large photopenic segment
(bracket) in the radiation ﬁeld. Note the absence of a correlative abnormality on CT in this region.
Fused indicates fused PET and CT image; AC, attenuation-corrected.

FIG 4. A 66-year-old woman with breast cancer. Sagittal CT (A), fused (B), and AC PET (C) images
demonstrate extensive osseous metastases throughout the spine with a number of lesions demonstrating varying degrees of increased uptake (arrows). Heterogeneous radiotracer uptake is due to
posttreatment changes. Absent radiotracer uptake suggests treated disease including in sclerotic vertebral bodies. This case demonstrates the superiority of PET/CT over conventional imaging in demonstrating a response to therapy. Fused indicates fused PET and CT image; AC, attenuation-corrected.

Osseous. The spine is the third most
common site of metastatic disease, following the lung and liver, with lung,
breast, and prostate cancer the most
commonly identified primary sites.15
The thoracic spine is the most commonly involved vertebral level, possibly
due to the relatively increased degree of
bone marrow volume to receive hematogenously spread metastatic deposits.2,16 [18F]FDG-PET is an important
tool for the diagnosis of early osseous
metastatic disease because increased
glucose metabolism in neoplastic cells
can become evident in even the earliest
cases of bone marrow infiltration.15,17
[18F]FDG-PET can demonstrate increased radiotracer uptake regardless of
lesion type, either osteolytic or osteoblastic, though due to a multitude of
factors including biochemical activity
of these lesions, the degree of [18F]FDG
uptake can be variable (Fig 4).15,18
PET/CT is superior to CT for the
evaluation of treatment response,
though imaging considerations in treatment response between PET/CT and
MR imaging are more complicated,
because specific disease processes may
alter which is the most accurate
method. While there are morphologic
MR imaging findings indicative of both
treatment response (eg, disappearance
of focal lesions, decreased size/number
of lesions) and disease progression (eg,
increased number/size of lesions or evolution from focal to diffuse neoplastic
infiltration), problems such as arrested
resolution of abnormalities despite
effective therapy that are thought to be
due to bone sclerosis, marrow fibrosis,
or necrosis as well as difficulty in evaluating disease activity on a scarred background and differences in MR imaging
techniques limit morphologic assessment.19 Advanced MR imaging techniques such as perfusion and diffusion
imaging can be used to supplement
morphologic assessment through their
assessment of tumor perfusion/permeability and cellular density/integrity,
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FIG 5. An 80-year-old woman with mucosa-associated lymphatic tissue lymphoma. Axial fused
(A), sagittal fused (B), and sagittal T2-weighted MR images (C) demonstrate an intensely hypermetabolic focus within the spinal column at T7–T8 (dashed arrow), which corresponds to a T2-isointense posterior epidural mass (solid arrow), which was found to be biopsy-proved metastatic
lymphoma. Fused indicates fused PET and CT image.

account for the most cases of epidural
involvement.21 Because thoracic spine
involvement is most common, in
approximately 60% of cases, epidural
disease has the greatest likelihood of
producing spinal cord injury.15,21,22
Epidural involvement can result from
hematogenous and lymphatic dissemination or by contiguous extension from
an adjacent vertebral body or through a
neuroforamen.3,15 While MR imaging is
superior to CT for evaluating epidural
involvement, superimposed PET does
improve the sensitivity of CT for detection, particularly when there is no associated adjacent osseous destruction (Fig
5).3 However, conventional PET alone
is too limited in its spatial resolution, at
about 4–5 mm, to differentiate epidural
from intradural disease, and while fused
CT imaging can improve its sensitivity,
suggested spinal canal disease should
prompt analysis with MR imaging.23

Intramedullary. Intramedullary spinal
cord metastasis (ISCM) is one of the
rare forms of systemic metastatic disease, comprising between 1% and 3% of
all patients with metastatic disease and
up to 9% of those with central nervous
system involvement.3 Approximately
50% of ISCMs arise from a primary
lung cancer, followed by breast cancer
as the second most common source.24,25
Up to one-third of these patients were
shown to have concurrent brain metastases, and up to one-fourth had additional leptomeningeal carcinomatosis.25
Numerous studies have demonstrated an increased prevalence of thoracic spinal cord involvement.24 These
FIG 6. A 54-year-old woman with breast cancer. Sagittal AC (A) and fused (B) images show a linlesions tend to show SUV uptake
ear segment of hypermetabolic activity (asterisk) in the thoracolumbar spinal column. This correlates with multiple enhancing intramedullary metastatic lesions (arrows) on corresponding
greater than the mediastinal blood pool,
sagittal T1-weighted postcontrast MR imaging (C). Fused indicates fused PET and CT image; AC,
with one study showing an average
attenuation-corrected.
SUVmax of 6.7.26,27 The morphology of
[18F]FDG uptake on PET tends to demonstrate round hypermetabolic foci in
respectively.20 Like MR imaging, [18F]FDG-PET also has issues
most cases (Fig 6). In addition, most MR imaging–visible ISCMs
when assessing only FDG-avid tumors as well as in the setting of
tend to be seen on PET as well.3 MR imaging features that correlate
flare reactions after G-CSF administration. Additionally, the choice
with visibility on PET include a larger lesion enhancement area, a
of imaging technique, notably with the development of PET/MR
larger extent of T2 signal abnormality, and an increased ratio of T2
imaging, should depend on the most accurate way to assess the prisignal abnormality to contrast enhancement.26
20
mary lesion, especially in cases of osseous metastases.
Leptomeningeal. Leptomeningeal disease or leptomeningeal carcinomatosis involves the presence of metastatic cells within the subarEpidural. With an incidence of up to 5%–10%, epidural metastatic
achnoid space of the brain and spinal cord. Etiologies range from
disease can be seen in up to 40% of patients with pre-existing nonbreast, small-cell lung cancer, melanoma, leukemia, and head and
spinal osseous metastases.21 Prostate, breast, and lung cancer
4
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neck cancers, with up to 2%–5% of
patients with breast cancer developing
leptomeningeal disease.3,28,29 The pathogenesis is thought to occur by either hematogenous spread, extension through
perivascular or perineural lymphatics,
or direct extension from adjacent tumor.2,3 Although leptomeningeal disease is often undiagnosed or clinically
silent, up to 98% of patients are symptomatic at the time of diagnosis.3,30
Leptomeningeal disease shows variable radiotracer uptake on [18F]FDGPET, ranging from 2.8 to 11.1 SUVmax
FIG 7. A 61-year-old man with chronic lymphocytic leukemia. Sagittal fused (A), AC (B), and postin one study.30 The uptake pattern
contrast T1-weighted MR images (C) demonstrate a hypermetabolic focus within the anterior thoappears similar to the respective patracic spinal canal (dashed white arrow) corresponding to a solid, enhancing intradural
extramedullary lesion (solid white arrow), which was found to be a schwannoma. There is additional
tern of contrast enhancement on MR
subtle hypermetabolic uptake predominantly along the inferior thoracic cord (dashed circle), which
imaging (Fig 7). A classic example, the
demonstrates a “sugar-coating” pattern of enhancement on MR imaging, consistent with leptome“bottle brush sign,” demonstrates FDGningeal spread of disease. Fused indicates fused PET and CT image; AC, attenuation-corrected.
avid disease within the lumbosacral spinal canal, extending through the sacral
neural foramina.3 One limitation, however, is that patients with only thin linear or fine multinodular
enhancement patterns on MR imaging demonstrated increased
false-negative findings on PET studies.30 This is because most leptomeningeal disease is below the spatial resolution threshold of [18F]
FDG-PET.3

Direct Extension

FIG 8. A 62-year-old man with penile cancer. Axial and coronal fused
(A and B) images demonstrate a long, nodular segment of radiotracer
uptake within the right pelvis suspicious for perineural spread of metastases (white arrows). Corresponding axial T1-weighted precontrast
and T1-weighted fat-saturated postcontrast MR imaging (C and D)
show nodular thickening and enhancement (dashed arrows) along
the right sacral nerve roots. Fused indicates fused PET and CT image.

FIG 9. An 87-year-old woman with lung cancer. Coronal CT (A), [18F]
FDG-PET (B), and PET/CT (C) images at the sacroiliac level demonstrate
bilateral linear lucencies through the sacral ala (white arrows), with corresponding linear radiotracer uptake (black arrows) compatible with
insufﬁciency fractures.

Perineural. Perineural spread of malignancy, an under-recognized route of disease spread, describes the process of neoplastic
dissemination along a nerve. This spread occurs along the pathway of least resistance, which is between the neural axon and surrounding perineural layer.31,32 The incidence of perineural tumor
spread ranges from 2.5% to 5%, with head and neck malignancies
the most common cause.32,33
[18F]FDG-PET demonstrates a sensitivity and specificity of
83% and 90%, respectively, in the detection of perineural tumor
spread.34 [18F]FDG-avid perineural lesions demonstrate linear or
curvilinear increased uptake along the associated nerve in a discontinuous or nodular pattern, similar to MR imaging enhancement
patterns (Fig 8).35 Perineural [18F]FDG uptake can be subtle, given
the low spatial resolution of [18F]FDG-PET.35 Additionally, apart
from the axial plane, one must use sagittal and coronal PET/CT
images as well as MIP images for proper assessment. Limited analysis has shown that the mean SUVmax in patients with perineural
metastatic spread is 7.1 (SD, 3.7).36 Secondary findings associated
with perineural spread relate to eventual denervation and associated muscle atrophy, with [18F]FDG-PET demonstrating increased
uptake within the affected muscle in the acute phase followed by
normalization in later stages and eventual decreased uptake in
chronic atrophy.35 False-positives with [18F]FDG-PET can be seen
in cases of inflammation from prior radiation or surgery, especially
within 1 month of surgery, with variable physiologic uptake in the
adjacent musculature and lymphoid tissue as well as due to coregistration artifacts during PET and CT fusion.31,35
AJNR Am J Neuroradiol :
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Direct Invasion. Direct invasion of tumor into the paraspinal soft tissues,
vertebral bodies, and spinal canal is a
frequent occurrence. Direct extension
to the spinal column can be either
from a primary site or a secondary site
such as a local metastatic lymph node
and is typically accompanied by a paraspinal soft-tissue mass, which is not
seen with hematogenous metastases.2

Nonmetastatic Disease of the
Spine
Trauma and Degeneration. Commonly
encountered nonmetastatic spinal pathologies can pose challenges in patients
in oncology undergoing [18F]FDG-PET
FIG 10. A 68-year-old woman with breast cancer. Axial (A) and coronal (C) CT and axial (B) and
imaging. Specifically, traumatic injuries
coronal (D) fused images demonstrate an intense focus of increased [18F]FDG uptake in the lumand age-related degenerative changes of
bar spine (dashed arrows) corresponding to a bulky osteophytic pseudoarthrosis on CT (solid
the spine are two important areas of
arrows), which can mimic blastic osseous metastases. Fused indicates fused PET and CT image.
concern because osseous metastatic
disease and fractures can present in a
similar fashion.37 Sacral insufficiency
fractures, in particular, can mimic pelvic osseous metastases; however, these tend to have more linear or H-shaped pattern of uptake
compared with the nodular patterns seen with metastatic disease
(Fig 9).11,38 A key differentiator is the transient nature of [18F]FDG
uptake in traumatic fractures, occurring due to the acute local
inflammatory state, with no considerable uptake generally identified
after 2–3 months.11,39
Degenerative and inflammatory arthropathies of the spine can
also show mild-to-intense [18F]FDG avidity. In these cases, the
degree of uptake is not necessarily linear in relation to the appearance of the degeneration but rather related to the degree of active
inflammation.11,37,40 These findings most commonly are found
near the vertebral body endplates and facet joints and include formation of synovial cysts, subchondral cysts, and osteophytosis,
which can be difficult to delineate from lytic and blastic osseous
metastases (Fig 10).11,37 Within the posterior elements, Baastrup
disease, characterized by inflammatory changes involving the
interspinous bursa and sclerosis of the spinous processes, can
demonstrate mild-to-moderate [18F]FDG uptake and mimic posterior element metastases.38

FIG 11. Upper row: A 50-year-old woman with multiple myeloma.
Sagittal fused (A) and CT (B) images demonstrate foci of intensely
increased FDG uptake (dashed arrows) in the thoracolumbar spine
vertebral bodies, corresponding to lytic myelomatous lesions (solid
arrows) on CT, which in the absence of a proper history, can appear
as lytic osseous metastases. Lower row: A 62-year-old woman with
breast cancer after recent chemotherapy. Sagittal fused image (C)
demonstrates an incidental photopenic lesion (dashed arrow) in the
posterior T6 vertebral body corresponding to a hemangioma on CT
(solid arrow). Fused indicates fused PET and CT image.
6
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Primary Osseous Lesions. Primary osseous pathology, while not
always neoplastic, is commonly encountered on routine surveillance oncologic imaging. These lesions, notably multiple myeloma and hemangiomas, can mimic metastatic disease and are
important considerations during the evaluation of osseous metastatic disease. Because myelomatous lesions are metabolically
active, fused imaging with CT can demonstrate hypermetabolic
lytic lesions, which can be easily confused with lytic metastases
(Fig 11).41,42 Hemangiomas, on the other hand, typically present
as incidental photopenic lesions on [18F]FDG-PET (Fig 11),
though occasionally internal hemorrhage and subsequent inflammatory changes of a vertebral hemangioma can demonstrate
hypermetabolism.43-45

FDG concentrations in adjacent tissues, below the reconstruction resolution, can underestimate true tumoral
metabolic activity.50,51 In response,
multiple partial volume correction
methodologies are increasingly being
developed to overcome this limitation,
critical for the assessment of treatment
response.
As calculation of total disease burden becomes of increasing clinical importance, alternatives in the method by
which [18F]FDG-PET data are analyzed
FIG 12. A 74-year-old man with thyroid cancer. Axial T2-weighted MR imaging (A), fused (B), and
has been studied. Particularly, total metAC (C) images demonstrate mild increased [18F]FDG uptake (dashed arrows) within the paraspinal
abolic tumor volume and total lesion
region at the C3–C4 level, appearing as a rounded soft-tissue density with neuroforaminal widenglycolysis have become more beneficial
ing/remodeling and intermediate T2 signal on MR imaging (solid arrow). Findings corresponded
than typical SUVs regarding true tumor
to a schwannoma, which, in the setting of known primary malignancy, can mimic perineural metastasis. Fused indicates fused PET and CT image; AC, attenuation-corrected.
burden, risk stratification, and outcomes.52,53 Of note, the calculation of
total lesion glycolysis uses SUVmean,
which, while affected by inter- and
intraobserver variability, is less sensitive
to image noise and reconstruction parameters and may make total lesion
glycolysis more beneficial in assessing tumor burden compared with
SUVmax.54-56 Although the time-consuming nature of manual quantification
and correction makes use of total lesion
glycolysis impractical for routine clinical
FIG 13. A 70-year-old man with rectal cancer. Axial CT (A), fused (B), and AC (C) images demonpractice, advancements in quantification
strate intense hypermetabolic uptake (dashed arrows) in the paraspinal musculature of the mid
software may make this limitation a
and lower thoracic spine, which corresponds to a hypodense region of phlegmon/developing abmoot point.57,58
scess on CT (solid arrow). Fluid cultures were positive for methicillin-resistant Staphylococcus
aureus. Fused indicates fused PET and CT image; AC, attenuation-corrected.
The potential applications of
recently developed total-body PET
imaging instruments have led to
exciting
advancements
in
clinical nuclear medicine and moBenign Neurogenic Lesions. Both primary malignant neoplasms
lecular
imaging.
With
their
increased axial FOV, these scanof the spinal cord (eg, astrocytoma, ependymoma) as well as beners
use
increased
detection
efficiency and scanner sensitivity
nign neurogenic lesions such as schwannomas can also mimic
31
to
considerably
improve
the
signal-to-noise ratio and tempometastatic disease on PET. Schwannomas, which are the most
ral
resolution,
all
while
using
a lower radiopharmaceutical
common of the peripheral nerve sheath tumors, demonstrate
18
dose,
which
can
be
specifically
useful in determining the
variable [ F]FDG uptake and, in the setting of known maligextent
of
disease
in
the
spine
and
spinal
cord.59,60 However, a
nancy, can appear similar to perineural spread of tumor, espemajor limitation for institutions outside of large research
cially ones that demonstrate mild uptake (Fig 12).46,47
institutions remains the cost of these scanners, particularly
the scintillation material, as well as data storage and processInfection. Given the overexpression of the glucose transport proing concerns.61
tein 1 subtype in macrophages, lymphocytes, and neutrophils, infectious processes can also demonstrate hypermetabolism on
[18F]FDG-PET mimicking metastatic disease (Fig 13).11,48 Of
particular note, tuberculous spondylitis can demonstrate multilevel subligamentous spread mimicking paravertebral lymphadenopathy in metastatic disease or lymphoma.49

Additional Considerations
Because the spatial resolution of [18F]FDG-PET is limited compared with conventional imaging, true disease assessment can be
considerably hindered by partial volume effects, in which [18F]

CONCLUSIONS
Spinal involvement by malignancy, either by direct extension or
distant metastases, is a relatively common occurrence in the workup and management of patients with cancer. While CT and MR
imaging play important roles in the assessment of spinal metastatic
disease, the importance and utility of [18F]FDG-PET cannot be
understated.3 Because PET and PET/CT are often used early in the
oncologic work-up and for surveillance imaging, it is critical for
radiologists to understand malignant and nonmalignant disease
AJNR Am J Neuroradiol :
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patterns and characteristics to make an accurate and useful
diagnosis.
Disclosure forms provided by the authors are available with the full text and
PDF of this article at www.ajnr.org.
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